Cost Analysis of Neuromuscular Blockers Purchased by Royal Medical Services During the Years 2018- 2020

Objective: to find out the most cost-effective drugs after analyzing the amounts purchased throughout the study period. Methods: Review tenders and/or sub-tenders during the years “2018 to 2020” for daily practice in all RMS hospitals. Comparative parameters include tender and sub-tender median unit price, total cost, onset and duration of action, side effect profile and rationale, and a set of recommendation groups and recommendation groups for each neuromuscular blocker drug purchased in 2014-2016. Conclusions that determine the economic feasibility of available projects that can be secured. Results: Suxamethonium had the lowest mean cost in one ampoule cost ($1.00), followed by Atracurium, Rocuronium ($1.22, $ 1.76) and cisatracurium ($2.6). the cost is calculated based on patient assuming to have a weight of 70 kg using one ampoule, further more analyzing sub tenders Atracurium had the lowest mean cost price in one ampoule ($1.63), followed by rocuronium ($2.78) and cisatracurium ($3.80). The main difference was in rocuronium due to high-cost difference between the main tenders and sub tenders. Conclusion: Additional investigations are essential to ensure that the procurements of NMBAs provide the most effective therapy and finest cost, as an investigation may contain an assessment between purchased prices of NMBAs in DRMS and in another institution such as the Ministry of Health throughout the same date